{"id":3109,"date":"2020-05-11T10:06:56","date_gmt":"2020-05-11T10:06:56","guid":{"rendered":"https:\/\/www.maxlee.info\/blog\/?p=3109"},"modified":"2020-05-22T10:12:18","modified_gmt":"2020-05-22T10:12:18","slug":"biotechnology-experts-who-understand-both-science-and-investing-are-skeptical-of-the-stock-markets-strength","status":"publish","type":"post","link":"https:\/\/www.maxlee.info\/blog\/news\/biotechnology-experts-who-understand-both-science-and-investing-are-skeptical-of-the-stock-markets-strength\/","title":{"rendered":"Biotechnology experts who understand both science and investing are skeptical of the stock market\u2019s strength"},"content":{"rendered":"<p>The pandemic\u2019s damage to the economy, and investing markets, may be long-lasting and worse than expected, they say<\/p>\n<p><!--more--><\/p>\n<figure id=\"attachment_3110\" aria-describedby=\"caption-attachment-3110\" style=\"width: 1200px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" src=\"\/blog\/wp-content\/uploads\/2020\/05\/MW-IE342_City_n_20200413195759_ZG-1200x675.jpg\" alt=\"The Montefiore Medical Center\u2019s Moses Campus in New York City. \" width=\"1200\" height=\"675\" class=\"size-large wp-image-3110\" srcset=\"https:\/\/www.maxlee.info\/blog\/wp-content\/uploads\/2020\/05\/MW-IE342_City_n_20200413195759_ZG-1200x675.jpg 1200w, https:\/\/www.maxlee.info\/blog\/wp-content\/uploads\/2020\/05\/MW-IE342_City_n_20200413195759_ZG-800x450.jpg 800w, https:\/\/www.maxlee.info\/blog\/wp-content\/uploads\/2020\/05\/MW-IE342_City_n_20200413195759_ZG-768x432.jpg 768w, https:\/\/www.maxlee.info\/blog\/wp-content\/uploads\/2020\/05\/MW-IE342_City_n_20200413195759_ZG.jpg 1320w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/><figcaption id=\"caption-attachment-3110\" class=\"wp-caption-text\">The Montefiore Medical Center\u2019s Moses Campus in New York City.<\/figcaption><\/figure>\n<p>Published: May 11, 2020 at 3:40 p.m. ET, By Michael Brush<\/p>\n<p>We\u2019re all virologists now, right?<\/p>\n<p>Well, maybe just enough to be dangerous, as the saying goes.<\/p>\n<p>While investors have driven a rally in the Dow Jones Industrial Average DJIA, S&amp;P 500 Index SPX, and Nasdaq Composite Index COMP since the late-March lows, it\u2019s ominous that people who know a lot more about science than the rest of us are scratching their heads about the optimism.<\/p>\n<p>They caution the coronavirus pandemic is nowhere near over, and it\u2019ll come back with a vengeance after any summer lull. If they\u2019re right, the current market rally is suspect because that\u2019ll be bad for the economy. It\u2019s particularly noteworthy that many of the skeptics come from the normally buoyant and bullish sell-side analyst community.<\/p>\n<p>Take Morgan Stanley biotech analyst Matthew Harrison.<\/p>\n<p>\u201cWhile we understand the desire for optimism, we also caution that the U.S. outbreak is far from over,\u201d he says. \u201cRecovering from the acute period in the outbreak is just the beginning and not the end.\u201d<\/p>\n<p>Harrison cautions the end won\u2019t arrive until a vaccine is available, in spring 2021 at the earliest.<\/p>\n<p>\u201cWe stress that only a vaccine will provide a true solution to this pandemic,\u201d he says.<\/p>\n<p>Reopening the economy, which began in some states late last week, will be a long and drawn-out affair that involves turning various forms of social distancing on and off in a trial-and-error period, he says. Many employees won\u2019t be able to go back to work during this phase.<\/p>\n<p>And large venues including sports arenas, concert halls and theme parks will stay shut, or have attendance capped. Economists at Morgan Stanley predict the economy won\u2019t return to pre-COVID-19 levels until the fourth quart of 2021. No V-shaped recovery \u2014 a quick down-and-up \u2014 in their forecast, in other words.<\/p>\n<p><strong>Next flu season<\/strong><\/p>\n<p>Virologist Michael Mina, a medical doctor and assistant professor of epidemiology at Harvard University, cautions that the COVID-19 could easily come back with a vengeance next flu season, possibly causing another shut down of the economy. It could spread even faster.<\/p>\n<p>The reason is there will be thousands of cases smoldering throughout the country that could serve as starting points for the spread, as opposed to a much smaller number from the get-go last winter.<\/p>\n<p>\u201cWe could see very rapid transmission, even faster than the first time,\u201d he says.<\/p>\n<p>Jefferies biotech analyst Michael Yee is also cautious.<\/p>\n<p>\u201cWe understand that the market wants to embrace the light at the end of the tunnel, but it is probably not that simple,\u201d he says.<\/p>\n<p>He says we need to see a lot more progress on therapies and vaccines before we can fully open up the economy and ease off social distancing.<\/p>\n<p><strong>No silver bullet<\/strong><\/p>\n<p>There\u2019s been optimism about Gilead\u2019s GILD remdesivir antiviral fixing the issue. The U.S. Food and Drug Administration (FDA) has given emergency-use authorization for remdesivir to treat COVID-19, based on results from a National Institute of Allergy and Infectious Diseases <a href=\"https:\/\/www.niaid.nih.gov\/news-events\/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19?mod=article_inline\">study<\/a>.<\/p>\n<p>The biotech experts I spoke with aren\u2019t convinced this will be much of a solution.<\/p>\n<p>\u201cRemdesivir doesn\u2019t look exceptionally effective,\u201d says Baird analyst Brian Skorney. \u201cWe remain skeptical of the magnitude of benefit.\u201d<\/p>\n<p>He\u2019s also cautious about the current plan to unlock the country on a regional basis. He thinks this is \u201cvery dangerous,\u201d given how much travel there is among states, and the low number of people who might have immunity because they\u2019ve been infected.<\/p>\n<p>\u201cIf current social-distancing protocols are relaxed too early, we could easily see a substantial second wave of COVID-19 disease,\u201d Skorney says.<\/p>\n<p><strong>Federal Reserve vs. COVID-19<\/strong><\/p>\n<p>One could argue that the caution in the science community is unwarranted because it doesn\u2019t fully understand the meaning of \u201cdon\u2019t fight the Fed.\u201d The Federal Reserve has unleashed enormous stimulus in response to the economic damage caused by the lockdown, and that kind of action normally prevails, according to this dictum.<\/p>\n<p>But even the Fed sides with the cautious virus experts and biotech analysts. Because of uncertainty about how the virus will evolve, the pandemic poses \u201cconsiderable risks\u201d to the economy, the Fed noted April 29. Fed Chairman Jerome Powell also worries about possible damage to production capacity due to a potential wave of bankruptcies among smaller companies, and extended unemployment. People begin to lose their skills and work habits when they stay unemployed for too long.<\/p>\n<p>Market technicians also have concerns. One of the hallmarks of the early stages of a bull market is that leadership is reasonably broad, and particularly prevalent among small-cap stocks, points out Baird chief investment strategist Bruce Bittles.<\/p>\n<p>In contrast, the rally off the late-March lows has been driven mainly by Facebook FB, Amazon AMZN, Apple AAPL, Netflix NFLX, Alphabet GOOG, GOOGL and health-care stocks. (The iShares NASDAQ Biotechnology Index exchange traded fund IBB is up for the year.)<\/p>\n<p>\u201cA sustainable advance requires participation from a broad group of sectors and individual stocks,\u201d says Bittles.<\/p>\n<p>He also points out the S&amp;P 500 recently traded near 19 times expected 12-month earnings. That already looks pricey, he says, because it is above the 10-year average, and it is higher than the valuation at the stock market\u2019s mid-February peak.<\/p>\n<p>But valuations could get much worse because analysts aren\u2019t done cutting their estimates. The more they cut, the higher the market valuation goes, even if stocks just stand still.<\/p>\n<p>\u201cHistorically, stocks generally do not go up during periods of declining earnings. Our economy will recover but expectations may have gotten ahead of tangible data,\u201d he says.<\/p>\n<p><strong>The good news<\/strong><\/p>\n<p>A least there\u2019s a good chance the stock market won\u2019t retest the late-March lows. Aside from Fed support of investor sentiment, there\u2019s a big pile of cash waiting to be deployed. After a lot of investors raised cash in March, the bargains did not last long enough for redeployment because the Fed and other central banks responded with such fast and forceful action.<\/p>\n<p>\u201cThey poured so much liquidity into the financial markets, many of the fire sales were rapidly extinguished,\u201d says Ed Yardeni of Yardeni Research. \u201cNow many investors who cashed out are sitting on a mountain of cash. That suggests that any significant selloff in the bond and stock markets might be limited, as those who had dashed for cash now seek opportunities to rebalance back into bonds and stocks.\u201d<\/p>\n<p><em>At the time of publication, Michael Brush had no positions in any stocks mentioned in this column. Brush has suggested FB, AMZN, AAPL, NFLX, GOOGL, IBB and XBI in his stock newsletter, Brush Up on Stocks. Brush is a Manhattan-based financial writer who attended Columbia Business School. Follow him @mbrushstocks.<\/em><\/p>\n<p>Source: <a href=\"https:\/\/www.marketwatch.com\/story\/biotechnology-experts-who-understand-both-science-and-investing-are-skeptical-of-the-stock-markets-strength-2020-05-09?mod=mw_more_headlines\">www.marketwatch.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The pandemic\u2019s damage to the economy, and investing markets, may be long-lasting and worse than expected, they say<\/p>\n","protected":false},"author":1,"featured_media":3110,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-3109","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/posts\/3109","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/comments?post=3109"}],"version-history":[{"count":0,"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/posts\/3109\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/media\/3110"}],"wp:attachment":[{"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/media?parent=3109"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/categories?post=3109"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maxlee.info\/blog\/wp-json\/wp\/v2\/tags?post=3109"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}